Elicio Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Elicio Therapeutics Inc Unternehmen

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.

Elicio Therapeutics Inc Informationen



BörsenkürzelELTX

Name des UnternehmensElicio Therapeutics Inc

IPO-datumFeb 05, 2021

CEOConnelly (Robert)

Anzahl der mitarbeiter32

WertpapierartOrdinary Share

GeschäftsjahresendeFeb 05

Addresse451 D Street, 5Th Floor

StadtBOSTON

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl02459

Telefon18572090050

Websitehttps://elicio.com/

BörsenkürzelELTX

IPO-datumFeb 05, 2021

CEOConnelly (Robert)

Führungskräfte von Elicio Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jay R. Venkatesan, M.D.

Director

170.22K

-10311.00%

Dr. Preetam Shah, Ph.D.

Principal Financial Officer, Principal Accounting Officer, Chief Strategy Officer

24.00K

+24000.00%

Ms. Yekaterina (Katie) Chudnovsky, J.D.

Independent Director

12.72K

+12725.00%

Ms. Karen J. Wilson, CPA

Independent Director

1.87K

--

Dr. Peter Demuth, Ph.D.

Chief Scientific Officer

743.00

+362.00%

Dr. Allen R. Nissenson, M.D.

Independent Director

--

Mr. Robert (Bob) Connelly

President, Chief Executive Officer, Director

--

Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.

Executive Vice President, Head - Research and Development, Chief Medical Officer

--

Dr. Julian Adams, Ph.D.

Independent Chairman of the Board

--

Ms. Carol Ashe

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jay R. Venkatesan, M.D.

Director

170.22K

-10311.00%

Dr. Preetam Shah, Ph.D.

Principal Financial Officer, Principal Accounting Officer, Chief Strategy Officer

24.00K

+24000.00%

Ms. Yekaterina (Katie) Chudnovsky, J.D.

Independent Director

12.72K

+12725.00%

Ms. Karen J. Wilson, CPA

Independent Director

1.87K

--

Dr. Peter Demuth, Ph.D.

Chief Scientific Officer

743.00

+362.00%

Dr. Allen R. Nissenson, M.D.

Independent Director

--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Mon, Feb 2

Aktionäre

Aktionärstypen

Aktionäre

Anteil

GKCC, LLC

30.97%

Knoll Capital Management, LLC

3.61%

The Vanguard Group, Inc.

2.84%

Actyus Private Equity SGIIC, S.A.

1.54%

Venkatesan (Jay R)

0.97%

Andere

60.07%

Aktionäre

Anteil

GKCC, LLC

30.97%

Knoll Capital Management, LLC

3.61%

The Vanguard Group, Inc.

2.84%

Actyus Private Equity SGIIC, S.A.

1.54%

Venkatesan (Jay R)

0.97%

Andere

60.07%

Aktionärstypen

Aktionäre

Anteil

Corporation

32.50%

Hedge Fund

4.86%

Investment Advisor

4.84%

Holding Company

2.75%

Individual Investor

2.33%

Investment Advisor/Hedge Fund

2.25%

Private Equity

0.31%

Research Firm

0.18%

Andere

49.97%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

58

2.05M

11.00%

--

2025Q3

59

2.05M

11.96%

+477.65K

2025Q2

52

1.58M

11.53%

-116.12K

2025Q1

59

1.67M

8.91%

+250.74K

2024Q4

54

504.27K

8.35%

-37.38K

2024Q3

58

541.64K

9.80%

-115.54K

2024Q2

70

657.30K

8.80%

+242.22K

2024Q1

96

415.08K

8.40%

-443.93K

2023Q4

102

540.87K

10.06%

+911.00

2023Q3

115

547.56K

11.25%

+45.29K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

GKCC, LLC

5.42M

30.97%

--

Jun 03, 2025

Knoll Capital Management, LLC

630.91K

3.61%

--

Sep 30, 2025

The Vanguard Group, Inc.

473.86K

2.71%

+19.24K

+4.23%

Sep 30, 2025

Actyus Private Equity SGIIC, S.A.

268.56K

1.54%

-587.82K

-68.64%

Sep 30, 2025

Venkatesan (Jay R)

170.22K

0.97%

-10.31K

-5.71%

Mar 24, 2025

Balyasny Asset Management LP

148.08K

0.85%

+148.08K

--

Sep 30, 2025

Geode Capital Management, L.L.C.

129.69K

0.74%

+8.86K

+7.33%

Sep 30, 2025

Connelly Robert

46.97K

0.27%

--

Mar 24, 2025

Susquehanna International Group, LLP

120.21K

0.69%

+103.18K

+606.14%

Sep 30, 2025

Marshall Wace LLP

86.53K

0.49%

+86.53K

--

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Micro-Cap ETF

0.02%

iShares Micro-Cap ETF

Anteil0.02%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Jun 01, 2023

Merger

10→1

Jun 01, 2023

Merger

10→1

Jun 01, 2023

Merger

10→1

Jun 01, 2023

Merger

10→1

Datum

Ex-Dividendentag

Art

Verhältnis

Jun 01, 2023

Merger

10→1

Jun 01, 2023

Merger

10→1

Jun 01, 2023

Merger

10→1

Jun 01, 2023

Merger

10→1